FDA Commissioner Scott Gottlieb said the agency would issue guidance in March about what drugs can be compounded in bulk for physicians' offices and hospitals without individual prescriptions. "Ultimately, there's no question that the framework we will be laying out will place more restrictions on what they can do," Gottlieb said.
An analysis of the best jobs of 2018 by US News & World Report ranked pharmacists 45th among the 100 professions selected by the magazine, scoring 6.5 of 10 overall, 8.7 for salary, 6 for job market, 4 for work-life balance and 4 for stress. Pharmacists were ranked 21st of the 100 most highly compensated jobs for 2018.
Oral Gilotrif, or afatinib, was approved to treat metastatic non-small cell lung cancer with nonresistant epidermal growth factor receptor gene mutations. The drug, produced by Boehringer Ingelheim, was previously approved as a second-line treatment for advanced squamous cell lung cancer.
Teva Pharmaceutical Industries' Trisenox, or arsenic trioxide injection, was approved in combination with tretinoin for treatment-naive patients with low-risk acute promyelocytic leukemia with the t(15;17) translocation or PML/RAR-alpha gene expression.
Celgene's Otezla, or apremilast, which is being developed as a treatment for pediatric patients with ulcerative colitis, was granted orphan status by the FDA. The drug was previously approved for psoriatic arthritis and plaque psoriasis and is in a midstage study for the treatment of adult patients with UC.
The first segment of a two-part early-stage trial to assess VBI Vaccines' immunotherapy candidate VBI-1901 has begun with the dosage of its first participant. The treatment targets cytomegalovirus antigens in patients with recurrent glioblastoma multiforme.
The 2018 federal budget will set funding levels for critical medical research infrastructure, determining whether promising research is supported at levels that produce breakthroughs and maintain US leadership in innovation, writes Claire Pomeroy, president of the Albert and Mary Lasker Foundation. Current proposals leave the NIH's purchasing power below prior levels and fail to adequately support other institutions on which biomedical innovation depends, including the CDC, National Science Foundation and Agency for Healthcare Research and Quality, Pomeroy writes.
The Maryland Health Care for ALL! Coalition is asking the state General Assembly to support its proposal to increase affordability of specialty and brand-name drugs. Maryland passed a law last year banning price gouging for off-patent and generic drugs.
The brick walls are not there to keep us out. The brick walls are there to give us a chance to show how badly we want something. Because the brick walls are there to stop the people who don't want it badly enough.